We fund translational research to move knowledge as quickly as possible from basic discovery to treatment of patients.

Since 2002, LUNGevity has invested in 200 research projects at 69 institutions in 24 states and the District of Columbia, for a total of $55,743,471.02.

Early Detection Research Award

Funded by LUNGevity Foundation in collaboration with The CHEST Foundation, the philanthropic arm of the American College of Chest Physicians

Clinton H. Doerr, MD
Mayo Graduate School of Medicine, Rochester, MN
Fluorescence in Situ Hybridization for the Detection of Lung Cancer

Tests that improve the ability to detect tumors at their earliest stages have the potential to reduce lung cancer mortality. Dr. Doerr developed three fluorescence in situ hybridization (FISH) probe sets for the detection of lung cancer in cell specimens. His research is assessing the reliability of these probe sets and routine cell examination for the detection of lung cancer in cell specimens obtained from bronchoscopy.

Targeted Therapeutics Research Award

Funded by LUNGevity Foundation in collaboration with The CHEST Foundation, the philanthropic arm of the American College of Chest Physicians

Alexei V. Bogolioubov, MD
Memorial Sloan Kettering Cancer Center, New York, NY
The Occurrence of Lung Cancer After Surgical Resection: Impact of New Staging System, Use of Adjuvant Chemotherapy and Value of Chest CT Versus Chest Radiograph

Surgery is often recommended for patients who have localized lung cancer. Dr. Bogolioubov is analyzing how fast lung cancer comes back after surgery to remove the primary tumor. He is also evaluating the role of chest CT radiography for post-operative follow-up.